Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis

Purpose of reviewTargeting the vascular endothelial growth factor (VEGF) pathway has had a significant impact in the therapy of cancer and intraocular neovascular disorders. Similar to other therapies, inherent/acquired resistance to anti-VEGF drugs may occur in cancer patients, leading to disease recurrence. This review describes recent findings on the role of myeloid cells in refractoriness or/and acquired resistance to such therapies. Recent findingsVarious myeloid cell types, including tumor-associated macrophages, Tie2-expressing monocytes and neutrophils, have been implicated in tumor angiogenesis. Several cytokines involved in the mobilization and/or proangiogenic effects of these cells represent therapeutic targets. CD11b+Gr1+ myeloid cells have been shown to render tumors refractory to angiogenic blockade by VEGF antibodies. This effect was mediated by the secreted protein Bv8, which is upregulated by granulocyte colony-stimulating factor. SummaryProgress in unraveling proangiogenic mechanisms dependent on various myeloid cell types has expanded our understanding of tumor angiogenesis and has generated a number of potential therapeutic targets.

[1]  Thijs J. Hagenbeek,et al.  PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth , 2010, Cell.

[2]  N. Ferrara.  Pathways mediating VEGF-independent tumor angiogenesis. , 2010, Cytokine & growth factor reviews.

[3]  Mohammad Tabrizi,et al.  A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models , 2010, Molecular Cancer Therapeutics.

[4]  N. Ferrara,et al.  Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. , 2009, Trends in pharmacological sciences.

[5]  E. Yu,et al.  Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder: possible effect of granulocyte colony-stimulating factor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Jain,et al.  VEGFR1-activity-independent metastasis formation , 2009, Nature.

[7]  G. Cheng,et al.  Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. , 2009, Cancer cell.

[8]  D. Kontoyiannis,et al.  Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients , 2009, Cancer.

[9]  L. Coussens,et al.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. , 2009, Cancer cell.

[10]  L. Naldini,et al.  Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy? , 2009, Biochimica et biophysica acta.

[11]  C. Lewis,et al.  Neutrophils: key mediators of tumour angiogenesis , 2009, International journal of experimental pathology.

[12]  M. Shibuya,et al.  M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis , 2009, The Journal of experimental medicine.

[13]  Sharmila Patel,et al.  Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease. , 2009, Current topics in medicinal chemistry.

[14]  Y. Meng,et al.  G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.

[15]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[16]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[17]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[18]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[19]  I. Kasman,et al.  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.

[20]  N. Ferrara,et al.  Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[21]  N. Ferrara,et al.  Role of myeloid cells in tumor angiogenesis and growth. , 2008, Trends in cell biology.

[22]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[23]  Craig Murdoch,et al.  The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.

[24]  Antonio Duarte,et al.  Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation , 2008, Nature.

[25]  J. Hamilton.  Colony-stimulating factors in inflammation and autoimmunity , 2008, Nature Reviews Immunology.

[26]  M. Shibuya.  Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. , 2008, BMB reports.

[27]  Napoleone Ferrara,et al.  Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective , 2006, Clinical Cancer Research.

[28]  V. Bronte,et al.  Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells , 2008, Immunological reviews.

[29]  Shahin Rafii,et al.  Migratory neighbors and distant invaders: tumor-associated niche cells. , 2008, Genes & development.

[30]  F. Marincola,et al.  Tumour immunity: effector response to tumour and role of the microenvironment , 2008, The Lancet.

[31]  L. Lang.  FDA approves sorafenib for patients with inoperable liver cancer. , 2008, Gastroenterology.

[32]  D. Carbone,et al.  Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. , 2008, Cancer cell.

[33]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[34]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[35]  F. Peale,et al.  Bv8 regulates myeloid-cell-dependent tumour angiogenesis , 2007, Nature.

[36]  M. Giacca,et al.  Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.

[37]  J. Talmadge.  Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy , 2007, Clinical Cancer Research.

[38]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[39]  D. Scheinberg,et al.  Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. , 2007, Genes & development.

[40]  C. Lewis,et al.  Expression of Tie-2 by Human Monocytes and Their Responses to Angiopoietin-21 , 2007, The Journal of Immunology.

[41]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[42]  K. Red-Horse,et al.  Endothelium-microenvironment interactions in the developing embryo and in the adult. , 2007, Developmental cell.

[43]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[44]  Claudio Campa,et al.  Targeting VEGF-A to treat cancer and age-related macular degeneration. , 2007, Annual review of medicine.

[45]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[46]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[47]  E. Stanley,et al.  Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. , 2006, Cancer research.

[48]  Yujia Dai,et al.  Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors , 2006, Molecular Cancer Therapeutics.

[49]  Holger Gerhardt,et al.  Pericytes limit tumor cell metastasis. , 2006, The Journal of clinical investigation.

[50]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[51]  Tatiana V. Petrova,et al.  Lymphangiogenesis in development and human disease , 2005, Nature.

[52]  J. Parham,et al.  Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Luigi Naldini,et al.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.

[54]  Thomas Hartmann,et al.  Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. , 2004, Cancer cell.

[55]  E. Stanley,et al.  Colony-Stimulating Factor-1 Blockade by Antisense Oligonucleotides and Small Interfering RNAs Suppresses Growth of Human Mammary Tumor Xenografts in Mice , 2004, Cancer Research.

[56]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[57]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[58]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[59]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[60]  D. Hanahan,et al.  Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. , 2003, The Journal of clinical investigation.

[61]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[62]  F. Peale,et al.  Identification of an angiogenic mitogen selective for endocrine gland endothelium , 2001, Nature.

[63]  C. Bullock,et al.  Identification of two prokineticin cDNAs: recombinant proteins potently contract gastrointestinal smooth muscle. , 2001, Molecular pharmacology.

[64]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[65]  M. Westphal,et al.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.

[66]  D. Barra,et al.  Bv8, a small protein from frog skin and its homologue from snake venom induce hyperalgesia in rats. , 1999, European journal of pharmacology.

[67]  M. Shibuya,et al.  Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[68]  F. Pixley,et al.  Biology and action of colony‐stimulating factor‐1 , 1997, Molecular reproduction and development.

[69]  L. Presta,et al.  The second immunoglobulin‐like domain of the VEGF tyrosine kinase receptor Flt‐1 determines ligand binding and may initiate a signal transduction cascade. , 1996, The EMBO journal.

[70]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[71]  J. Winer,et al.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.

[72]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[73]  Charles J. Sherr,et al.  The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF 1 , 1985, Cell.

[74]  N. Wolmark,et al.  A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  G. Sonpavde,et al.  Axitinib for renal cell carcinoma. , 2008, Expert opinion on investigational drugs.

[76]  N. Ferrara,et al.  VEGF inhibition: insights from preclinical and clinical studies , 2008, Cell and Tissue Research.

[77]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[78]  N. Pryer,et al.  SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model , 2004, Clinical & Experimental Metastasis.

[79]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.